Sex Is Associated with Adalimumab Side Effects and Drug Survival in Patients with Crohnʼs Disease
Authors:
Open Access
- 1 January 2017
- journal article
- research article
- Published by Oxford University Press (OUP) in Inflammatory Bowel Diseases
- Vol. 23 (1) , 75-81
Abstract
Background. Adalimumab (ADA) is an effective treatment for Crohn's disease (CD). In rheumatology, sex differences concerning the response to ADA therapy have beKeywords
This publication has 29 references indexed in Scilit:
- High intra-uterine exposure to infliximab following maternal anti-TNF treatment during pregnancyAlimentary Pharmacology & Therapeutics, 2011
- Population pharmacokinetic analysis of infliximab in patients with ulcerative colitisEuropean Journal of Clinical Pharmacology, 2009
- Adalimumab for Crohn’s disease with intolerance or lost response to infliximab: a 3‐year single‐centre experienceAlimentary Pharmacology & Therapeutics, 2009
- Early clinical experience with adalimumab in treatment of inflammatory bowel disease with infliximab‐treated and naïve patientsAlimentary Pharmacology & Therapeutics, 2008
- Infliximab Pharmacokinetics in Inflammatory Bowel Disease PatientsTherapeutic Drug Monitoring, 2008
- Adalimumab for maintenance treatment of Crohn’s disease: results of the CLASSIC II trialGut, 2007
- Adalimumab for Maintenance of Clinical Response and Remission in Patients With Crohn’s Disease: The CHARM TrialGastroenterology, 2007
- Human Anti–Tumor Necrosis Factor Monoclonal Antibody (Adalimumab) in Crohn’s Disease: the CLASSIC-I TrialGastroenterology, 2006
- The Influence of Age and Sex on the Clearance of Cytochrome P450 3A SubstratesClinical Pharmacokinetics, 2005
- How Important Are Gender Differences in Pharmacokinetics?Clinical Pharmacokinetics, 2002